Please assess the completion status of the following clinical trial:

Trial Title: Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis: Adult Myelodysplastic Syndrome (≥18 years).~* Revised IPSS: very low. low - intermediate~* Having received 5-20 packed red blood cell units~* Serum ferritin ≥300 ng/ml~* Transferrin saturation ≥ 60%~* Chelation naïve~* Capability to provide informed consent~Exclusion Criteria:~* Patients aged \<18 years old~* Higher risk (revised IPSS) MDS (Intermediate 2, high)~* Cumulative transfusion story of \> 20 packed red cell units~* Creatinine Clearance (CrCL): \<60 ml/min. Patients with CrCl of 40-60ml/min will be included only individually if no other renal risk factors are present.~* Serum creatinine \>2 x ULN at screening. If borderline serum creatinine will be measured within 7-10 days and the mean value will be used for eligibility criteria.~* Significant proteinuria as indicated by a urinary protein/creatinine ratio \> 0.5 mg/mg in a non-first void urine sample (or alternatively in two of three samples obtained for screening).~* ECOG performance status \>2.~* Left ventricular ejection fraction \< 50% by echocardiography~* A history of repeated hospitalization for congestive heart failure.~* Systemic diseases that would prevent study treatment (e.g. uncontrolled hypertension, cardiovascular, renal, hepatic, metabolic, etc.)~* Clinical or laboratory evidence of chronic Hepatitis B or Hepatitis C (definition of chronic hepatitis follows EASL 2017 criteria).~* History of HIV positive test result (ELISA or Western blot).~* Treatment with systemic investigational drug within 4 weeks or topical investigational drug within 7 days of study start.~* ALT or AST over 3 times superior to ULN at screening.~* ANC \< 500/ microL~* Platelets transfusion dependency~* Total bilirubin over 1.5 times superior to ULN at screening (patients with Gilbert syndrome are allowed to enter the study)~* Diagnosis of Child score C liver cirrhosis.~* Patients participating in another clinical trial other than an observational registry study.~* Patients with a history of another malignancy within the past 3 years, with the exception of basal skin carcinoma or cervical carcinoma in situ or completely resected colonic polyps carcinoma in situ.~* History of non-compliance to medical regimens, or patients who are considered potentially unreliable and/or not cooperative.~* Presence of a surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug.~* Pregnant, intending-to-become pregnant, or breast-feeding patients.~* Women of potential maternity age who do not agree to practice effective contraceptive methods fo the entire study duration.~* History of drug or alcohol abuse within the 12 months prior to enrollment.~* Hypersensitivity to the active substance or to any of the excipients.~* Inability to provide a valid informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).